Back to News
Market Impact: 0.15
Nanjing Leads Biolabs To Present Opamtistomig Phase IIb Study At ESMO 2026
Source: Nasdaq
Healthcare & Biotech
Nanjing Leads Biolabs announced an update concerning its pivotal registrational Phase IIb trial of opamtistomig (LBL-024) monotherapy in advanced extrapulmonary neuroendocrine carcinoma. The provided article text is incomplete and does not disclose the trial result, efficacy, safety data, regulatory outcome, or financial implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum